Literature DB >> 9571605

High dose-rate brachytherapy treatment delivery: report of the AAPM Radiation Therapy Committee Task Group No. 59.

H D Kubo1, G P Glasgow, T D Pethel, B R Thomadsen, J F Williamson.   

Abstract

The goals of this task group are to examine the current high dose-rate (HDR) treatment delivery practices and to prepare a document to assure safe delivery of HDR treatments. The document consists of detailed HDR procedures for design of an HDR brachytherapy program, staffing and training, treatment specific quality assurance, and emergency procedures. The document provides an extensive quality assurance (QA) check list. It reviews all aspects of HDR treatment delivery safety, including prescription, treatment plan, treatment delivery, and radiation safety.

Mesh：

Year:  1998        PMID： 9571605     DOI： 10.1118/1.598232

Source DB:  PubMed          Journal:  Med Phys        ISSN： 0094-2405            Impact factor:   4.071


  44 in total

1.  Point/Counterpoint. Only a therapist should operate an HDR unit for patient treatments.

Authors:  Maria F Chan; Chunli Claus Yang; Colin G Orton
Journal:  Med Phys       Date:  2015-10       Impact factor: 4.071

2.  American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy.

Authors:  Akila N Viswanathan; Sushil Beriwal; Jennifer F De Los Santos; D Jeffrey Demanes; David Gaffney; Jorgen Hansen; Ellen Jones; Christian Kirisits; Bruce Thomadsen; Beth Erickson
Journal:  Brachytherapy       Date:  2012 Jan-Feb       Impact factor: 2.362

3.  A Monte Carlo study on dose distribution validation of GZP6 (60)Co stepping source.

Authors:  Mohammad Taghi Bahreyni Toossi; Maliheh Abdollahi; Mahdi Ghorbani
Journal:  Rep Pract Oncol Radiother       Date:  2012-11-21

4.  Dose distribution verification for GYN brachytherapy using EBT Gafchromic film and TG-43 calculation.

Authors:  Somayeh Gholami; Hamid Reza Mirzaei; Ali Jabbary Arfaee; Ramin Jaberi; Hassan Ali Nedaie; Seied Rabi Mahdavi; Eftekhar Rajab Bolookat; Ali S Meigooni
Journal:  Rep Pract Oncol Radiother       Date:  2016-07-18

5.  The report of Task Group 100 of the AAPM: Application of risk analysis methods to radiation therapy quality management.

Authors:  M Saiful Huq; Benedick A Fraass; Peter B Dunscombe; John P Gibbons; Geoffrey S Ibbott; Arno J Mundt; Sasa Mutic; Jatinder R Palta; Frank Rath; Bruce R Thomadsen; Jeffrey F Williamson; Ellen D Yorke
Journal:  Med Phys       Date:  2016-07       Impact factor: 4.071

Review 6.  A review of dosimetric impact of implementation of model-based dose calculation algorithms (MBDCAs) for HDR brachytherapy.

Authors:  Yousif A M Yousif; Alexander F I Osman; Mohammed A Halato
Journal:  Phys Eng Sci Med       Date:  2021-06-17

7.  Tolerance of the vaginal vault to high-dose rate brachytherapy and concomitant chemo-pelvic irradiation: Long-term perspective.

Authors:  Orit Kaidar-Person; Roxolyana Abdah-Bortnyak; Amnon Amit; Alexander Nevelsky; Alison Berniger; Raquel Bar-Deroma; Rahamim Ben-Yosef; Abraham Kuten
Journal:  Rep Pract Oncol Radiother       Date:  2013-10-16

8.  Evaluation of safety in a radiation oncology setting using failure mode and effects analysis.

Authors:  Eric C Ford; Ray Gaudette; Lee Myers; Bruce Vanderver; Lilly Engineer; Richard Zellars; Danny Y Song; John Wong; Theodore L Deweese
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-04       Impact factor: 7.038

Review 9.  Current status and perspectives of brachytherapy for prostate cancer.

Authors:  Yasuo Yoshioka
Journal:  Int J Clin Oncol       Date:  2009-02-20       Impact factor: 3.402

10.  Strategies for effective physics plan and chart review in radiation therapy: Report of AAPM Task Group 275.

Authors:  Eric Ford; Leigh Conroy; Lei Dong; Luis Fong de Los Santos; Anne Greener; Grace Gwe-Ya Kim; Jennifer Johnson; Perry Johnson; James G Mechalakos; Brian Napolitano; Stephanie Parker; Deborah Schofield; Koren Smith; Ellen Yorke; Michelle Wells
Journal:  Med Phys       Date:  2020-04-15       Impact factor: 4.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.